HeimSGIOY • OTCMKTS
add
Shionogi 2 ADR Representing 1 Ord Shs
Við síðustu lokun
6,93 $
Dagbil
6,94 $ - 7,03 $
Árabil
6,22 $ - 9,11 $
Markaðsvirði
1,87 bn JPY
Meðalmagn
233,49 þ.
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(JPY) | sep. 2024info | Breyting á/á |
---|---|---|
Tekjur | 116,38 ma. | -4,00% |
Rekstrarkostnaður | 52,93 ma. | -3,66% |
Nettótekjur | 52,50 ma. | 9,30% |
Hagnaðarhlutfall | 45,11 | 13,86% |
Hagnaður á hvern hlut | — | — |
EBITDA | 53,13 ma. | -5,14% |
Virkt skatthlutfall | 8,28% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(JPY) | sep. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 303,40 ma. | 20,22% |
Heildareignir | 1,46 bn | 3,34% |
Heildarskuldir | 145,93 ma. | -18,09% |
Eigið fé alls | 1,31 bn | — |
Útistandandi hlutabréf | 850,69 m. | — |
Eiginfjárgengi | 0,00 | — |
Arðsemi eigna | 8,22% | — |
Ávöxtun eigin fjár | 9,10% | — |
Peningaflæði
Breyting á handbæru fé
(JPY) | sep. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | 52,50 ma. | 9,30% |
Handbært fé frá rekstri | 45,30 ma. | 220,14% |
Reiðufé frá fjárfestingum | -17,63 ma. | 47,30% |
Reiðufé frá fjármögnun | -1,11 ma. | 94,50% |
Breyting á handbæru fé | 21,45 ma. | 158,43% |
Frjálst peningaflæði | 8,02 ma. | 135,46% |
Um
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Framkvæmdastjóri
Stofnsett
1878
Höfuðstöðvar
Vefsvæði
Starfsfólk
4.959